Introduction
Atherosclerosis represents the most common cause of cardiovascular diseases. A prominent risk factor for atherosclerosis is hyperlipidaemia, i.e. high levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) in the circulation. Currently, reducing circulating atherogenic lipoproteins with lipid-lowering medication, such as statins and PCSK9 inhibitors, remains the major strategy to prevent acute cardiovascular events. However, only 30% of all cardiovascular events can be prevented by such treatment strategies, 1 illustrating the need for new therapeutic strategies.
Brown fat is present in mammals as well as in (adult) humans and is an emerging target to combat hyperlipidaemia and atherosclerosis. [2] [3] [4] Cold exposure, the best known physiological activator of brown fat, leads to the release of noradrenalin from sympathetic nerves that innervate brown fat. Noradrenalin binds to the b3-adrenergic receptor (b3-AR) on brown adipocytes, resulting in their activation to produce heat. 5 As the b3-AR is highly expressed on brown and white adipocytes, and white fat does not substantially contribute to energy expenditure, the coldstimulated activation of brown fat inducing thermogenesis can be pharmacologically mimicked by selective b3-AR agonists such as CL316,243 compound, one of the most selective b3-AR agonists available. 6 Since heat generation is an energy consuming process, activated brown fat takes up large amounts of nutrients from the circulation, mainly TGderived fatty acids from TG-rich lipoproteins [TRLs; i.e. very-low-density lipoproteins (VLDL) and chylomicrons]. 7, 8 As a result, brown fat activation accelerates the formation and uptake of cholesterol-enriched lipoprotein remnants by the liver, thereby protecting from hyperlipidaemia and atherosclerosis development. 7 In addition to reducing cholesterolenriched TRL remnant levels, b3-AR agonism also improves high-density lipoprotein (HDL) functionality as reflected by increased reverse cholesterol transport (RCT). 7, 9 Collectively, these studies show that b3-AR agonism increases cholesterol delivery towards the liver via both accelerating the clearance of cholesterol-enriched TRL remnants and improving HDL-mediated RCT.
Hepatic cholesterol turnover is mainly mediated by faecal excretion as bile acids (BAs) and, to a lesser extent, by faecal excretion of neutral sterols. 10 Hepatocytes synthesize primary BAs, i.e. cholic acid (CA) and chenodeoxycholic acid (CDCA), via the so-called classic pathway; while CDCA can also be synthesized via an alternative pathway. 11 In mice, but not in humans, CDCA can be converted into more hydrophilic species, the so-called muricholic acids (MCAs). 12 Newly synthesized BAs are temporarily stored in the gallbladder and are secreted into the duodenum upon food ingestion to serve as detergents for absorption of nutrients. 13 By the enzymatic action of gut bacteria, part of the primary BAs are converted into secondary BAs. In the terminal ileum, 95% of BAs are reabsorbed by active transport with remaining BAs excreted in faeces. Reabsorbed BAs mainly circulate back through the portal vein to the liver completing one cycle of enterohepatic circulation. 14 BA synthesis is regulated by enterohepatic circulation of BAs via farnesoid X receptor (FXR), which inhibits transcription of genes in BA synthesis. 15 The enterohepatic circulation can be interrupted by BA sequestrants, which increases clearance of plasma (V)LDL-C by promoting conversion of hepatic cholesterol into BAs and up-regulation of hepatic LDL receptors. In fact, BA sequestrants such as Cholestyramine and Colesevelam have been proven to be effective to treat dyslipidaemia and prevent cardiovascular diseases. 16 Interestingly, both short-term and long-term activation of brown fat increases cholesterol delivery towards the liver. 7, 17 Moreover, we previously showed that long-term activation of brown fat significantly increased hepatic cholesterol accumulation. 17 Since BA synthesis is the main pathway for hepatic cholesterol catabolism, short-term activation of brown fat indeed has been linked to increased BA production and increased faecal BA excretion. 18 However, how long-term brown fat activation influences BA metabolism and whether manipulation of BA metabolism on top of brown fat activation would lead to additional benefits on cholesterol metabolism and atherosclerosis development has not been studied yet. Thus, the aim of the current study was to evaluate the effects of prolonged brown fat activation via b3-AR agonism on cholesterol and BA metabolism. In addition, we assessed whether inhibiting intestinal BA reabsorption beneficially influences the effects of prolonged b3-AR agonism on cholesterol turnover and atherosclerosis development. To this end, we treated hyperlipidaemic APOE*3-Leiden(E3L).CETP mice, a well-established model for human-like lipoprotein metabolism and atherosclerosis, 19, 20 with or without the selective b3-AR agonist CL316,243 to activate brown fat for 9 weeks. In subsequent experiments, E3L.CETP mice were treated with vehicle, CL316,243 alone, the BA sequestrant Colesevelam alone to inhibit intestinal BA reabsorption, or the combination of both for a period of 4 or 12 weeks.
Methods
Detailed description of the Methods section is available in the Supplementary material online.
Animals and treatments
Hemizygous APOE*3-Leiden (E3L) mice were crossbred with homozygous human cholesteryl ester transfer protein (CETP) transgenic mice to generate heterozygous E3L.CETP mice. 21 At the age of 10-12 weeks, female mice were fed a Western-type diet (WTD; Altromin, Germany) containing 15% cacao butter, 1% corn oil, and 0.15% (w/w) cholesterol.
In a first experiment, 17 mice were randomized into two groups after a run-in period of 6 weeks on WTD. Mice were subsequently treated 5 days/week with the selective b3-AR agonist CL316,243 (symbol: b; Tocris Bioscience Bristol, UK; 20 lgÁmouse -1 ) or vehicle (phosphatebuffered saline, symbol: -) by subcutaneous injections between 14:00 and 16:00 h for an additional 9 weeks.
In a second experiment, mice were randomized into two groups after a run-in period of 3 weeks on WTD and subsequently received WTD supplemented without or with 0.15% (w/w) Colesevelam (symbol: c; Genzyme Europe B.V., The Netherlands). After an additional run-in period of 3 weeks, mice in each treatment group were again randomized into two subgroups and additionally treated 5 days/week with vehicle or CL316,243 by subcutaneous injection for additional 4 weeks. This resulted in the following four treatment groups: (i) vehicle (-), (ii) CL316,243 (b), (iii) Colesevelam (c), and (iv) Colesevelam þ CL316,243 (c þ b).
In a third experiment, the set-up was similar to the second experiment, with the exception that mice were treated with CL316,243 or vehicle for 12 weeks.
Food intake and body weight were monitored weekly. Body composition (i.e. body fat and lean mass; EchoMRI-100; EchoMRI, Houston, TX, USA) was evaluated every 2 weeks. At the end of each experiment, mice were euthanatized by CO 2 suffocation and unconscious mice were perfused with ice-cold saline via cardiac perfusion, and various organs were isolated for further analysis.
These animal experiments were approved by the Animal Ethical Committee of Leiden University Medical Center, Leiden, The Netherlands (DEC 12252-02). All animal procedures were performed conform to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.
Faecal and plasma bile acid analysis
Faeces were collected over a 24-h period and dried at room temperature, weighed, and homogenized. BA composition was determined in an 
Biliary bile acid collection and composition analysis
Mice were anaesthetized by intraperitoneal injection with Hypnorm (1 mLÁkg -1 ; Janssen Pharmaceuticals) and Diazepam (10 mgÁkg -1 ; Actavis). The bile duct was ligated and the gallbladder was cannulated to collect BAs. Hepatic bile was collected for 15 min and the average of bile flow per minute was calculated. BA compositions were determined in 5 lL bile by GC as described above. Biliary cholesterol levels were determined using an enzymatic kit from Roche Diagnostics (Mannheim, Germany).
Gene expression analysis
Gene expression analysis was performed as described in the Supplementary material online. The primer sequences used are listed in Supplementary material online, Table S1.
Plasma lipid assays and lipoprotein profiles
Plasma was assayed for TG and total cholesterol (TC) using enzymatic kits from Roche Diagnostics (Mannheim, Germany) as described in the Supplementary material online. The distribution of TG and cholesterol over lipoproteins was determined in pooled plasma by fast-performance liquid chromatography (FPLC) using a Superose 6 column (GE Healthcare, Piscataway, NJ, USA).
Hepatic lipid content
Liver lipids were assayed as described in the Supplementary material online.
2.7
In vivo plasma decay and hepatic uptake of TG-rich lipoprotein-like particles TRL-like particles (80 nm), double-labelled with glycerol tri[ 3 H]oleate ([ 3 H]TO) and [ 14 C]cholesteryl oleate ([ 14 C]CO), were prepared as described previously. 22 Mice were fasted for 4 h and injected (t = 0) intravenously with 200 mL of TRL-like particles (1 mg TG per mouse). Blood samples were taken from the tail vein at 2, 5, 10, and 15 min after injection to determine the plasma decay of [ 3 H]TO and [ 14 C]CO. After 15 min, livers were isolated and weighted, and 3 H-and 14 C-activity were quantified.
Atherosclerosis quantification
Hearts were collected, fixed in phosphate-buffered 4% formaldehyde, and embedded in paraffin. Four sections of the aortic root area with 50 mm intervals were used and stained with haematoxylin-phloxine-saffron for histological analysis. Lesions were categorized for lesion severity according to the guidelines of the American Heart Association adapted for mice 23 and classified as mild lesions (types 1-3) and severe lesions (types 4-5). Monoclonal mouse antibody M0851 against smooth muscle cell (SMC) actin was used to quantify the SMC area, Sirius Red staining was used to quantify the collagen area, and rat monoclonal antibody MAC3 was used to quantify macrophage area as described. 17 Lesion area was determined with Image J Software (version 1.50i).
Statistical analysis
Differences between two groups were determined using the unpaired two-tailed Student's t-test. Differences between four groups were determined using one-way analysis of variance (ANOVA) with the LSD post hoc test, which however increases the alpha risk as it does not correct for multiple comparisons. The square root of the lesion area was transformed to linearize the relationship with the plasma TC exposure. Univariate regression of analyses was performed to test for significant correlations between atherosclerotic lesion area and plasma TC exposure. Multiple regression analysis was performed to predict the contribution of plasma TC exposures to the atherosclerotic lesion area. Probability values less than 0.05 were considered statistically significant. All statistical analyses were performed with the GraphPad Prism 7 for Windows.
Results

Prolonged b3-AR agonism decreases faecal bile acid excretion and increases plasma bile acid levels
We previously fed female E3L.CETP mice a WTD and treated them with the b3-AR agonist CL316,243 (b) or vehicle (-) for 9 weeks, and observed that prolonged b3-AR agonism significantly increases liver TC levels. 17 Since BA synthesis is the major route of hepatic cholesterol catabolism, we now analysed BAs level in faeces and plasma of this 9 weeks treatment study. 17 Notably, prolonged b3-AR agonism reduced faecal total BA output into faeces (-31%; Figure 1A ), which equals hepatic BA synthesis rate under steady-state conditions. While faecal CAderived BA secretion only tended to be reduced (-27%, P = 0.07; Figure 1B ), faecal CDCA-derived BA secretion was significantly reduced (-35%; Figure 1C ). The faecal excretion of secondary BAs was unaffected ( Figure 1D ). In plasma, total BA levels were markedly increased (þ258%; Figure 1E ), and this was due to an increase in both CA-derived BAs (þ295%; Figure 1F ) and CDCA-derived BAs (þ217%; Figure 1G ). b3-AR agonism also increased plasma secondary BA levels (þ33%, Figure 1H ), and the proportion of conjugated BAs (þ55%, Supplementary material online, Figure S1A ). Collectively, these data suggest that prolonged b3-AR agonism decreases faecal BA output related to stimulation of BA reuptake.
Prolonged b3-AR agonism reduces the expression of genes involved in bile acid synthesis
To further reveal how b3-AR agonism regulates BA metabolism, hepatic mRNA expression of genes involved in BA metabolism was investigated. While b3-AR agonism only tended to reduce Cyp7a1, it significantly reduced Hsd3b7 (-57%) and Cyp8b1 (-40%) (Supplementary material online, Figure S1B ), all of which are involved in the classical BA synthesis pathway. In addition, b3-AR agonism reduced Cyp27a1 (-53%) and Cyp7b1 (-38%) (Supplementary material online, Figure S1C ), which are involved in the alternative BA synthesis pathway. This data is consistent with the reduced faecal BA excretion, implying a reduced hepatic BA synthesis rate under steady-state conditions. b3-AR agonism also tended to reduce Abcg5 (-31%, P = 0.06) and Bsep expression (-27%, P = 0.05) (Supplementary material online, Figure S1D Figure S1E ), involved in the basolateral BA secretion from the liver towards the systemic circulation. b3-AR agonism tended to reduce Oatp1a1 expression (-60%, P = 0.06) and significantly reduced Ntcp expression (-37%) (Supplementary material online, Figure S1F ), involved in the uptake of reabsorbed BAs by the liver.
Bile acid sequestration reverses b3-ARmediated reduction of faecal bile acid output and normalizes elevated plasma bile acid levels
Because we observed that b3-AR agonism decreases faecal BA excretion and increases plasma BAs, we next assessed whether inhibition of intestinal BA reabsorption, by using the BA sequestrant Colesevelam, would stimulate faecal BA loss and prevent the increase in plasma BAs during prolonged b3-AR agonism. Mice were treated for 4 weeks with vehicle, the b3-AR agonist alone, a low dose of the BA sequestrant alone (Colesevelam 0.15% in the WTD, w/w), or the combination of b3-AR agonism and BA sequestration. b3-AR agonism, Colesevelam, or the combination did not influence food intake (Supplementary material online, Figure S2A ), body weight (Supplementary material online, Figure  S2B ), or body lean mass (Supplementary material online, Figure S2C ). As expected, b3-AR agonism tended to reduce body fat mass (P = 0.09; Supplementary material online, Figure S2D ) and significantly reduced gonadal white adipose tissue weight (gWAT; Supplementary material online, Figure S2E ). The combination of b3-AR agonism and BA sequestration significantly reduced body fat mass (Supplementary material online, Figure S2D ) and gWAT weight (Supplementary material online, Figure S2E ) as compared to vehicle. Liver weight was not significantly influenced by b3-AR agonism alone or in combination with BA sequestration (Supplementary material online, Figure S2F ).
Compared to vehicle, b3-AR agonism alone, BA sequestration alone, and the combination of b3-AR agonism and BA sequestration all increased bile flow (þ43%, þ33%, and þ38% vs. vehicle, respectively; Figure 2A ). The biliary BA secretion rate was not influenced by the different treatments ( Figure 2B) . Additionally, biliary cholesterol excretion rate was increased by b3-AR agonism (þ75% vs. vehicle), but not by BA sequestration or the combination of b3-AR agonism and BA sequestration ( Figure 2C) .
Furthermore, although 4 weeks b3-AR agonism did not significantly decrease faecal excretion of total BAs ( Figure 2D ) and CA-derived BAs (Figure 2E) , excretion of CDCA-derived BAs was significantly decreased (-50% vs. vehicle; Figure 2F ). BA sequestration on top of b3-AR agonism strongly increased faecal excretion of total BAs (þ91% vs. vehicle; þ234% vs. b; þ47% vs. c; Figure 2D ), CA-derived BAs (þ201% vs. vehicle; þ357% vs. b; Figure 2E ), and CDCA-derived BAs (þ109% vs. b; Figure 2F ). In addition, BA sequestration on top of b3-AR agonism markedly increased faecal secondary BA excretion (þ122% vs. vehicle; þ274% vs. b; þ40% vs. c; Figure 2G ). Finally, although the b3-AR agonism-induced increase in plasma BA levels was not as pronounced as after 9 weeks of treatment, concomitant BA sequestration normalized Figure 2K ). Taken together, these data indicate that inhibition of BA reabsorption by BA sequestration reverses b3-AR agonism-induced reduction of faecal BA excretion, i.e. stimulates hepatic BA synthesis under these conditions, and normalizes b3-AR agonism-mediated increased plasma BA levels.
Bile acid sequestration on top of b3-AR agonism reverses hepatic cholesterol accumulation and further improves plasma cholesterol levels
As the BA sequestrant Colesevelam on top of b3-AR agonism strongly increased faecal BA excretion and normalized plasma BA levels, we evaluated whether the addition of BA sequestration could also correct the b3-AR agonism-induced hepatic cholesterol accumulation as shown previously 17 and further lower plasma lipids. We confirmed that b3-AR agonism significantly increased hepatic TC levels (þ26%). BA sequestration alone reduced hepatic TC levels as compared to vehicle (-41%) ( Figure 3A) . Importantly, BA sequestration on top of b3-AR agonism also largely reduced hepatic TC levels as compared to vehicle (-37%) and b3-AR agonism alone (-50%) ( Figure 3A) , and to similar levels as BA sequestration alone. Hepatic TG and PL contents were not influenced by any of the treatments (Figure 3B and C) .
Next, we assessed the effect of BA sequestration on top of b3-AR agonism on plasma lipid levels. After 4 weeks of treatment, plasma TG levels were reduced by b3-AR agonism (-52%) and tended to be reduced by BA sequestration alone (-33%, P = 0.07) as compared to vehicle. BA sequestration on top of b3-AR agonism reduced plasma TG levels as compared to vehicle (-74%) and also as compared to BA sequestration alone (-62%) ( Figure 3D ). In addition, BA sequestration alone reduced plasma TC levels as compared to vehicle (-47%). BA sequestration on top of b3-AR agonism also reduced plasma TC levels as compared to vehicle (-55%) and to b3-AR agonism alone (-49%; Figure 3E ).
Since cholesterol can be carried in plasma by either pro-or atherogenic lipoprotein classes, we also determined the distribution of cholesterol over plasma non-HDL and HDL. Plasma non-HDL-C levels tended to be reduced by b3-AR agonism alone (-27%, P = 0.05) and were significantly reduced by BA sequestration alone (-55%) and BA sequestration Figure 3F ) as compared to vehicle. Moreover, BA sequestration on top of b3-AR agonism further reduced non-HDL-C levels as compared to b3-AR agonism alone (-56%; Figure 3F ). In addition, both b3-AR agonism alone (þ34%), and in combination with BA sequestration (þ52%; Figure 3G ) increased antiatherogenic HDL-C levels as compared to vehicle. Taken together, these findings indicate that BA sequestration on top of b3-AR agonism reverses the b3-AR agonism-induced hepatic cholesterol accumulation and further reduces plasma non-HDL-C levels.
Bile acid sequestration does not interfere with the b3-AR agonism-induced plasma clearance and hepatic uptake of cholesterol-enriched TRL remnants
As b3-AR agonism increases the formation and hepatic uptake of cholesterol-enriched TRL remnants 7, 17 and BA sequestration on top of b3-AR agonism further lowers plasma non-HDL-C levels, we next studied whether BA sequestration on top of b3-AR agonism influenced the hepatic uptake of cholesterol-enriched TRL remnants. Hereto, we treated mice with the BA sequestrant Colesevelam on top of the b3-AR agonist CL316,243 for 12 weeks. Similar as in the 4-week study, b3-AR agonism alone and in combination with BA sequestration, but not BA sequestration alone, reduced body fat mass (-37% and -38%, respectively; Supplementary material online, Figure S3A ) and gWAT weight (-55% and -61%, respectively; Supplementary material online, Figure S3B ) as compared to vehicle. In agreement with previous studies, 7,17 we also observed that b3-AR agonism induced substantial brown fat activation and browning of WAT as evidenced from decreased lipid contents in BAT (Supplementary material online, Figure S3C ) and subcutaneous WAT (scWAT, Supplementary material online, Figure S3D ), while BA sequestration on top of b3-AR agonism did not further add to these effects. The mRNA expression of genes related to intestinal BA reabsorption in the ileum is shown in Supplementary material online, Table S2 . b3-AR agonism significantly increased the mRNA expression of BA transporters Asbt and Ost-b. Furthermore, b3-AR agonism markedly increased Shp and Fgf15 mRNA expression in the ileum, while the expression of these genes was reduced by BA sequestration, and normalized by the combination treatment.
In line with the 4-week intervention, 12 weeks of b3-AR agonism alone improved dyslipidaemia by reducing plasma TG (-35%; Figure 4A ), mainly via reducing (V)LDL-TG ( Figure 4B) , TC (-31%; Figure 4C) , and non-HDL-C (-45%; Figure 4D ) levels as compared to vehicle, while increasing HDL-C levels (þ52%; Figure 4E ). The decrease in (V)LDL-C and increase in HDL-C by b3-AR agonism alone and on top of BA sequestration was confirmed by FPLC ( Figure 4F) . As compared to b3-AR agonism alone, BA sequestration on top of b3-AR agonism did not influence plasma TG ( Figure 4A) , but further lowered plasma TC (-24%; Figure 4C ) and tended to further reduce non-HDL-C levels (-32%, P = 0.06; Figure 4D ). Next, the total plasma TC and non-HDL-C exposure during the treatment period were calculated. The combination treatment further reduced both the total plasma TC exposure (-18%; Figure 4G ) and non-HDL-C exposure (-20%; Figure 4H ) as compared to b3-AR agonism alone.
After 12 weeks of treatment, we evaluated the plasma clearance and hepatic uptake of intravenously injected glycerol tri[ 3 H]oleate (triolein, Figure 4J) , and increased the hepatic uptake of the formed cholesterol-enriched TRL remnants (þ25%, Figure 4K ) as compared to vehicle. Additional BA sequestration did not further accelerate the plasma clearance of [ 3 H]TO-derived activity and [ 14 C]CO and also did not further increase the hepatic uptake of [ 14 C]CO ( Figure 4I-K) as compared to b3-AR agonism alone.
Bile acid sequestration on top of b3-AR agonism tends to further attenuate atherosclerosis development
To investigate if the beneficial effects of BA sequestration on top of b3-AR agonism on BA and cholesterol metabolism would translate in a further protection against atherosclerosis development, we evaluated the atherosclerotic lesion area in the root of the aortic arch after 12 weeks of treatment. As expected, b3-AR agonism alone decreased atherosclerotic lesion area throughout the aortic root ( Figure 5A and B) , resulting in lower mean atherosclerotic lesion area as compared to vehicle (-56%; Figure 5C ). BA sequestration on top of b3-AR agonism strongly attenuated atherosclerotic lesion area by -79% as compared to vehicle; and as compared to b3-AR agonism alone tended to further reduce the atherosclerotic lesion area (-54%; P = 0.16) ( Figure 5C ). The total plasma TC exposure during the study strongly correlated with the square root (SQRT)-transformed lesion area (b = 2.14, R 2 = 0.40; P < 0.001; Figure 5D ). Moreover, although atherosclerotic lesion severity was not significantly mitigated by any treatment (Supplementary material online, Figure S4A ), b3-AR agonism increased the proportion of lesion-free valves as compared to vehicle (þ122%), which was further increased by additional BA sequestration (þ199% vs. vehicle; þ34% vs. b; Figure 5E ). Proportions of SMC area and collagen area were not affected by any of the treatments ( Figure 5F , G and Supplementary material online, Figure  S4B ), while BA sequestration on top of b3-AR agonism further decreased the percentage of macrophage area within the lesion (-34% vs. vehicle; -26% vs. b; Figure 5H and Supplementary material online, Figure  S4B ) and increased the stability index defined by the ratio of stable markers (i.e. SMC area and collagen area) vs. the unstable marker (i.e. macrophage area) (þ70% vs. vehicle; þ44% vs. b; Figure 5I ).
Taken together, BA sequestration in addition to b3-AR agonism tends to further reduce atherosclerosis development, an effect that is strongly related to its plasma cholesterol-lowering effect.
Discussion
Activating brown fat is a promising strategy to combat hypercholesterolaemia by increasing the flux of lipoprotein-associated cholesterol towards the liver, thereby exerting atheroprotective effects. 7, 9 The aim of this study was first to evaluate the effects of prolonged brown fat activation, via b3-AR agonism, on hepatic cholesterol turnover. Secondly, we aimed to assess the effects of BA sequestration on top of brown fat activation on hepatic cholesterol and BA metabolism as well as atherosclerosis development. We uncovered that the increased hepatic cholesterol content by prolonged b3-AR agonism as shown previously, 17 was accompanied by increased plasma BA levels and decreased faecal BA excretion. It is likely that more efficient BA reabsorption from the gut is mostly responsible for these effects, since biliary BA (representing both newly synthesized BAs and cycled BAs within the enterohepatic circulation) output was actually increased under these conditions. Indeed, concomitant BA sequestration by Colesevelam markedly increased faecal BA excretion and lowered the hepatic cholesterol content. As a result, combining BA sequestration with b3-AR agonism further reduced plasma cholesterol levels and tended to further reduce atherosclerosis development and also increase plaque stability as compared to b3-AR agonism alone.
Previously, we observed that prolonged b3-AR agonism in mice increases the delivery of cholesterol to the liver via the uptake of cholesterol-enriched TRL remnants 7 and HDL-C 9 and this increased flux of cholesterol towards the liver results in a moderate hepatic cholesterol accumulation. 17 In fact, 4 weeks of b3-AR agonism already clearly increased the hepatic cholesterol level. In the current study, we further show that prolonged b3-AR agonism decreased faecal BA excretion and increased plasma BA levels. Since there is negligible excretion of BAs via the urine and skin, hepatic BA synthesis from cholesterol equals faecal BA excretion under steady-state conditions to maintain BA pool size. 24 Our data therefore demonstrate that prolonged b3-AR agonism decreases hepatic BA synthesis in mice. This is supported by the reduced expression of genes involved in the classical and alternative BA synthesis pathways. The observation that the biliary BA secretion rate was not decreased after prolonged b3-AR agonism, but rather tended to be increased, can be explained by the fact that the biliary BAs represent both newly synthesized BAs as well as BAs that are recycled within the enterohepatic circulation. b3-AR agonism increases BA reabsorption from the gut (i.e. increasing cycled BAs within the enterohepatic circulation), which is responsible for the overall increased biliary BA output. In line with our study, Baskin et al. 25 recently showed that the b3-AR agonist mirabegron increased gallbladder size in humans, which could be caused by an increased BA-induced bile flow upon brown fat activation.
The current study shows that the effects of prolonged brown fat activation on BA metabolism partly differ from the effects of short-term brown fat activation. Previous observations by us and others with shortterm brown fat activation by means of b3-AR agonism and cold exposure (i.e. 1 week) showed increased expression of genes related to BA synthesis 18 and increased faecal BA excretion. 9, 18 This difference observed with treatment duration is likely explained by an initial transient induction of BA synthesis upon brown fat activation, that is driven by the increased hepatic influx of cholesterol, the main substrate for BA synthesis, 26 and dependent on hepatic induction of Cyp7b1. 18 After prolonged brown fat activation, the higher concentration of BAs in the gut likely stimulate BA reabsorption from the gut to prevent BA loss from the body. Subsequently, both BAs in the gut, via induction of FGF15 production, and circulating BAs target the hepatic FXR pathway and inhibit BA synthesis via a well-established feedback mechanism. 15 Based on our findings, 4 weeks of b3-AR agonism is sufficient to induce such an inhibitory feedback on BA synthesis. Collectively, available data indicate that brown fat activation initially increases BA synthesis and thereby faecal BA excretion, while prolonged brown fat activation, decreases hepatic BA synthesis and thereby induces hepatic cholesterol accumulation. It appears that under these conditions reabsorption of BAs from the gut becomes more efficient, which, possibly in combination with suppressed expression of hepatic BA uptake transporters, leads to elevated plasma levels of BAs. High hepatic cholesterol and BA levels may affect liver function by inducing liver inflammation. 27, 28 Since prolonged b3-AR agonism increased plasma levels of BAs, including secondary BAs, and decreased faecal BA excretion, we reasoned that prolonged b3-AR agonism induces reabsorption of BAs from the gut. In fact, b3-AR agonism clearly increased the expression of Asbt, the . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . predominant transporter for the uptake of the luminal BAs, 29 and Ost-b, a basolateral BA transporter which plays a key role in BA efflux in the ileum. 30, 31 In addition to increasing the expression of BA transporters, b3-AR agonism increased plasma secondary BA levels. Intestinal anaerobic bacteria, i.e. Eubacterium and Clostridium 32 are capable to deconjugate the liver-derived BAs and convert primary BAs into secondary BAs, such as LCA (omega-MCA in mice) and DCA, which has a high affinity to ASBT in the ileum. 33 The activity of those obligatory anaerobic bacteria would be largely impaired when faeces were collected and placed in the presence of oxygen. Thus, the effect of b3-AR agonism on increasing intestinal BA reabsorption may be attributed to upregulation of Asbt and Ost-b expression in the ileum as well as increased conversion of primary BAs into secondary BAs in the gut.
Colesevelam is a BA sequestrant that reduces the reabsorption of BAs from the gut, with a preference for relatively hydrophobic species like deoxycholic acid (DCA; i.e. the main secondary BA derived from CA). 26 Likely via this mechanism, Colesevelam particularly increased faecal secondary BA excretion. Interruption of the enterohepatic circulation by a very low dosage of Colesevelam is not complete and increased hepatic synthesis and sufficient BAs within the circulation resulted in a 
